Compare Iamgold Corporation Ordinary Shares (IAG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iamgold Corporation Ordinary Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? Iamgold Corporation Ordinary Shares trades at $17.22 (market cap $10.39B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Iamgold Corporation Ordinary Shares is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Iamgold Corporation Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iamgold Corporation Ordinary Shares for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IAG | SYRE | |
|---|---|---|
Market Cap | $10.39B | $7.52B |
Volume | 2,784,290 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $24.57 | $108.92 |
52-Week Low | $10.96 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.43B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAG trades at $18.27, down 1.62% today, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with a P/E of 9.23, net income margin of 31.4%, and ROE of 29.53%. Recent earnings show mixed results with two beats and one miss in the last three quarters. Analyst consensus is moderately bullish with a $22.00 price target, representing 20% upside potential from current levels.
IAG presents a compelling value opportunity with attractive valuation metrics and strong profitability. Key catalysts include Q3 2026 earnings release in November and operational optimization initiatives. Risks include commodity price volatility, execution challenges at mining operations, and potential cost pressures from rising fuel prices that could impact profitability.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iamgold Corporation Ordinary Shares
IAMGOLD is a gold mining company with operations in Canada. It also explores and develops gold properties.
Read more on IAG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
